At a time when many weed companies are struggling to keep their shareholders happy, spare a thought for some investors in Supreme Pharmaceuticals (SL.C), who dipped out last week as their company stock dropped from $1.60 down to $1.25.

In Facebook groups and on messageboards, there were naysayers aplenty keen to dance on the graves of weak hands, tossing out reasons why Supreme would ‘see $0.50 soon’ and that it was worth no more than any old late stage applicant, being as it has a license to grow, but not yet sell.

At Equity.Guru, we pointed out several reasons why Supreme’s lack of sale license just didn’t matter.

Like, there’s a huge and growing lack of weed supply out there, so Supreme’s harvests are being banked in their safe, with no concern about best before dates because, hey, dried and vacuum sealed and growing in value by the day…

And that Supreme has $60m+ in cash, which it’s using to expand its footprint and which means it doesn’t give a shit if it makes $0 revs this quarter or not because payroll will be met.

And that a few million in revs from sales to other LPs wouldn’t make a dent in the overall value of the thing anyway, with its $217 million market cap.

And, that the company hasn’t even been in a rush to call in Health Canada for its final license inspection because, hey, what’s the rush? Perfect the grow, zero in on hot strains, and plan for rec.

I guess that message got through. I announced Tuesday that I would be buying Supreme at the crazy low prices it was at (I got $1.26), because to me it’s a pension lockbox. Buy it, sit on it, don’t give a shit if it drops or rises in the short term because $1.26 isn’t a price you’ll ever see again.

I did the same thing back when it was at $0.16 a year and a bit ago, selling at $0.22 a week later. I did it again on a dip to $0.70 six months or so ago, selling as it soon hit a buck. This will be my third Supreme plunder, coming in when hands get weak and making a nice turnaround, only this time I think I’ll hang in.

It’s turned out to be a good move so far. Supreme has jumped over the last few days, even as the market – and the weed market at that – has gone red.

By close Wednesday, it was at $1.42. By close today, $1.56. We’re up 21.2% in two days.

Of course, it may drop tomorrow – or it may go on another rip. But it doesn’t really matter, either way, because the ultimate goal for a company like this is to be sitting on your cheap shares when, in 2020 or 2021, it’s supplying a million kilos of weed a year to pharma companies and bread companies and drug store chains.

$1.56 a share? I’ll buy that all day. Because you’re either a flipper, and you spend all day obsessing over whether the market sees what you see, right now, because margins! Or you’re an investor, and you put your money with people and a plan that have shown they know how to build value.

Giddyup, Supreme. Take me to the promised land.

— Chris Parry

FULL DISCLOSURE: The author, as stated, owns Supreme Pharma stock. The company is not an Equity.Guru marketing client.

Written By:

Chris Parry

A multi-Webster Award winner for excellence in BC journalism, Parry is the founder and publisher of Equity.Guru, which he built with the specific plan to blend old school reporting with stock promotion, in a way that puts the emphasis on truth, high standards, and ethics. Parry is a veteran of TV, radio, and print, and consults with public companies to help them figure out their storylines, lay down achievable milestones, and improve their communication with shareholders, while also posting regular deep dive analysis of companies in the public spotlight.

More By This Author
Medical marijuana
Supreme Pharmaceuticals
0 0 votes
Article Rating
Notify of
Newest Most Voted
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x